Kïdo Home, a virtual education platform, has launched out of a Houston-area school. Photo via Getty Images

The coronavirus pandemic has spawned an array of digital innovations in education, and one of those innovations has been hatched right here in Houston.

Kïdo, an international network of preschools, recently introduced its first-ever virtual learning platform, with Kïdo's school in Rice Village serving as the U.S. launchpad. The new platform, called Kïdo Home, is offering free trials for parents in the Houston, Austin, and Dallas-Fort Worth areas. Kïdo Home is in the midst of enrolling students nationwide.

The virtual platform in the U.S. rolled out August 7, with classes starting Sept. 1. The Kïdo Home platform already had been up and running in Dubai, Hong Kong, and London, where Kïdo operates brick-and-mortar schools.

Kïdo Home is made up of small-group classes held online and led by trained instructors. Given the massive interruption of in-person education caused by the pandemic, the platform fills a void for 2- to 6-year-olds.

A study conducted this summer by the National Institute for Early Education Research at Rutgers University's Graduate School of Education found U.S. preschoolers were losing two to four months of critical learning due to pandemic-provoked school closures. According to a nationwide survey of parents, nearly three-fourths of American preschoolers had been affected by pandemic shutdowns that started in March. Many parents reported their distance-learning alternatives were lacking, with less than half receiving support for virtual learning within two months of preschool closures.

"Perhaps 10 percent of preschool children received a robust replacement for in-person preschool attendance," Steve Barnett, senior co-director of the Rutgers institute, says in a release.

Kïdo's Rice Village school serves as the U.S. launchpad for the new platform. Photo via kido.school

Adapted from the Kïdo Early Years Program — which blends the Waldorf Steiner, Reggio Emilia, and Montessori methodologies — Kïdo Home is designed to foster imagination, social well-being, motor skills, and creativity in students through its year-long curriculum.

Kïdo Home's key features include interactive touchscreen literacy and math modules, weekly one-on-one sessions with accredited instructors, and monthly home-activity kits covering art, STEM, literacy, and physical development. Those kits complement the online learning components.

Parents receive weekly updates and monthly assessments regarding their child's progress in the virtual program.

"We saw the need to provide a high-quality, affordable, and engaging virtual learning platform months ago when the pandemic was impacting our preschools in Hong Kong," Houston-based Deepanshu Pandita, U.S. CEO of Kïdo, says in a release. "We've conducted in-depth research that showcases the importance of investing in early childhood education, what the right amount of screen time is, and how to keep children engaged remotely."

Kïdo Home's daily two-hour, real-time video lessons eventually will include second-language immersion, just like Kïdo's brick-and-mortar schools do.

The average class ratio for Kïdo Home is around one instructor for every eight students. Minimal to no parental support is required during these classes. The program costs $350 a month.

Kïdo operates brick-and-mortar locations in Houston, Austin, Hong Kong, Dubai, and London, all of which are open. The Houston school, Kïdo's first in the U.S., debuted in May. The Austin location opened in July. Although a free trial of the virtual platform is available in Dallas-Fort Worth, Kïdo doesn't have a school there.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas ranks high on new best states for investors report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.